• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Perkins Sherrie L

    1/8/25 4:10:39 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $HSDT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Perkins Sherrie L

    (Last) (First) (Middle)
    C/O HELIUS MEDICAL TECHNOLOGIES, INC.
    642 NEWTOWN YARDLEY ROAD, SUITE 100

    (Street)
    NEWTOWN PA 18940

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    HELIUS MEDICAL TECHNOLOGIES, INC. [ HSDT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    01/06/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $0.7292 01/06/2025 A 10,732 (1) 01/05/2035 Class A Common Stock 10,732 $0 10,732 D
    Explanation of Responses:
    1. Grant to the Reporting Person of a stock option under the Issuer's 2022 Equity Incentive Plan. 50% of the options vested immediately upon grant, and the remaining options vest in a series of four (4) successive equal quarterly installments on the last day of each quarter starting on March 31, 2025, subject to the Reporting Person's continued service through each applicable vesting period.
    /s/ Emily J. Johns, by Power of Attorney 01/08/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $HSDT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HSDT

    DatePrice TargetRatingAnalyst
    11/15/2021Outperform → Market Perform
    Noble Capital Markets
    More analyst ratings

    $HSDT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting

      -PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis- -Presentation of full PoNSTEP study results expanded upon top line data previously reported- NEWTOWN, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Deborah Backus, PT, Ph.D., FACRM- Vice President of Research and Innovation at Atlanta's Shepard Center presented the positive results from the PoNS Therapeutic Experience Program, or

      6/12/25 6:59:59 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device

      -Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network reimbursement is only the first step towards expanding third-party paid access to PoNS- NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced an authorized claim for payment for the PoNS Device from a third major healthcare provider, Aetna Healthcare. "The recent reimbursement approvals from two major

      6/11/25 7:00:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius Medical Technologies Announces Pricing of $9.1 Million Public Offering

      NEWTOWN, Pa., June 04, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the pricing of its public offering of an aggregate of 2,768,600 shares of its Class A common stock (or common stock equivalents), and warrants to purchase up to 2,768,600 shares of common stock, at a combined public offering price of $3.27 per share and accompanying warrants. Each Warrant will expire two and one-half (2.5) years from the issuance, will be immediately exercisable upon issuance at an initial exercise price of $7.3575 pe

      6/4/25 9:12:02 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Helius Medical Technologies Inc.

      SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

      11/8/24 5:12:24 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Helius Medical Technologies Inc.

      SC 13G - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

      5/14/24 4:15:39 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Helius Medical Technologies Inc. (Amendment)

      SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

      2/13/24 7:09:07 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    SEC Filings

    See more
    • SEC Form 424B4 filed by Helius Medical Technologies Inc.

      424B4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)

      6/5/25 8:00:49 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form EFFECT filed by Helius Medical Technologies Inc.

      EFFECT - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)

      6/5/25 12:15:33 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius Medical Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)

      6/4/25 8:31:47 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    Leadership Updates

    Live Leadership Updates

    See more
    • Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device

      -Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network reimbursement is only the first step towards expanding third-party paid access to PoNS- NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced an authorized claim for payment for the PoNS Device from a third major healthcare provider, Aetna Healthcare. "The recent reimbursement approvals from two major

      6/11/25 7:00:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting

      NEWTOWN, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced it will highlight the results of a new study confirming the therapeutic regimen and sustained efficacy of its Portable Neuromodulation Stimulator (PoNS®) device for people with multiple sclerosis (MS) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. The event runs from May 28-31 at the Phoenix Convention Center in Phoenix. Deborah Backus, PT, Ph.D., FACRM – Vice President of Research and Innovation at Atlanta's Shepherd Center, one of six sit

      5/20/25 7:00:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius Medical Technologies, Inc. Appoints Paul Buckman to its Board of Directors

      NEWTOWN, Pa., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced the appointment of Paul Buckman to its Board of Directors, effective September 10, 2021. Mr. Buckman will serve as Chair of the Company's Audit Committee and as a member of its Compensation and Nominating & Governance Committees. "Paul is a highly accomplished executive with more than 30 years of experience in the medical device sector, including senior leadership positions at some of the most well-regarded companies in the industry," said Blane Walter, Chairman of Helius' Board of Directors. "I

      9/14/21 7:05:00 AM ET
      $HSDT
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    Financials

    Live finance-specific insights

    See more
    • Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device

      NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today provided updates on its efforts to achieve fair market access for its Portable Neuromodulation Stimulator (PoNS) device and announced plans to host a business update call today at 9:00am ET.   "We disagree with the proposed pricing for the PoNS Mouthpiece and are disappointed CMS has once again mapped the Controller pricing to a code for fundamentally different technology," said Dane Andreeff, Helius' President and Chief Executive Officer. "I

      11/18/24 8:01:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius Medical Technologies, Inc. to Release Second Quarter 2024 Financial Results on August 12, 2024

      NEWTOWN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its second quarter 2024 financial results on Monday, August 12, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius' progress and plans surrounding the U.S. commercialization of PoNS® as follows: Date:Monday, Augus

      8/6/24 4:36:06 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024

      NEWTOWN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its first quarter 2024 financial results on Monday, May 13, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius' progress and plans surrounding the U.S. commercialization of PoNS® as follows: Date: Monday, May 13, 2

      5/10/24 9:00:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Andreeff Dane bought $8,229 worth of shares (1,284 units at $6.41) (SEC Form 4) (Amendment)

      4/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      2/15/24 4:06:00 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Andreeff Dane bought $40,475 worth of shares (5,000 units at $8.10) (SEC Form 4)

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      12/15/23 7:00:42 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Andreeff Dane bought $25,675 worth of shares (4,006 units at $6.41) (SEC Form 4)

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      12/4/23 8:30:12 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Helius Medical Tech downgraded by Noble Capital Markets

      Noble Capital Markets downgraded Helius Medical Tech from Outperform to Market Perform

      11/15/21 10:55:44 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Noble Capital Markets initiated coverage on Helius Medical with a new price target

      Noble Capital Markets initiated coverage of Helius Medical with a rating of Outperform and set a new price target of $20.00

      3/24/21 8:02:45 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LADENBURG THALM/SH SH initiated coverage on Helius Medical Technologies

      LADENBURG THALM/SH SH initiated coverage of Helius Medical Technologies with a rating of Buy

      2/12/21 8:21:57 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CFO and Treasurer Mathiesen Jeffrey S

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      1/8/25 4:10:32 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Director Perkins Sherrie L

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      1/8/25 4:10:39 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Favit-Van Pelt Antonella R.

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      1/8/25 4:10:36 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care